The online reference source for the interventional NeuroRadiology, Neurology and NeuroSurgery community

HEMERA 1, a phase 1 trial of carboxyhemoglobin oxygen delivery for revascularization in acute stroke

Last update on June 27, 2023

Join Italo Linfante (USA) and Rodrigo Rivera (Chile) as they discuss HEMERA 1, a phase 1 trial investigating carboxyhemoglobin oxygen delivery for revascularization in acute stroke. This innovative study aims to explore the potential benefits of using carboxyhemoglobin to enhance oxygen delivery to affected brain regions during an acute stroke, with the goal of improving revascularization and patient outcomes. Watch video.

This interview was filmed at Linnc Paris 2023 .

On the same subject

Perspectives - Key findings and perspectives from the LASTE study, a trial of thrombectomy for stroke with a large infarct of unrestricted size

June 24, 2024

Perspectives - How to manage current challenges in the endovascular treatment of large infarcts?

June 24, 2024

Perspectives - How will the latest clinical studies on subacute and chronic subdural hematoma treatment impact our practice?

June 24, 2024

Most relevants studies from the LINNC Trials book

June 5, 2024

COMMAND Trial

June 4, 2024

LINNC Trials book 2025

June 3, 2023

Phenox Inc. announces the presentation of the PROST Clinical Trial at the International Stroke Conference in Dallas.

February 13, 2023

[Irvine, CA] - phenox Inc. a leading medical device company in the Neurovascular industry, announced the presentation of the primary results of The pRESET for Occlusive Stroke Treatment (...

Phenox Inc. a Wallaby Medical Company, announces the FDA 510k Clearance of the pRESET® Thrombectomy Device for the treatment of acute ischemic stroke

February 5, 2023

Phenox Inc., a leading medical device company in the Neurovascular industry, announced today that its pRESET Thrombectomy Device has received FDA clearance for use to treat acute ischemic stroke. T...

Come and join us across the globe